Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AbCellera Biologics

Explore full profile

Innovator in antibody discovery for therapeutics, and immune profiling for vaccine research

Vancouver, CanadaFounded 2012Biotech & Life Sciences
Valuation $1.38B Market cap · Aug/2026
Revenue $32M Latest reported FY

At a glance

Status
Listed
Founded
2012
Headquarters
Vancouver, Canada
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom
News AbCellera launches $200M stock offering to fund lead cancer programme Aug 11, 2026

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later7 investors entered at this stage

  • Northview LifeSciences
  • Viking Global Investors
  • The University of British Columbia
  • OrbiMed
  • Peter Thiel
  • Eli Lilly
  • Presight Capital

Talent

Book a demo to see the people
Employees mapped 590 incl. 22 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 13 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇨🇦 Canada82%
🇦🇺 Australia9.8%
🇺🇸 United States5.7%
🇮🇪 Ireland1.3%
🇮🇳 India0.6%
Top 5 of 8 shown
Web traffic by country
29K monthly visits
across markets
🇨🇦 Canada37.2%
🇺🇸 United States26.2%
🏳️ Korea11.4%
🏳️ Republic of8.6%
🇦🇺 Australia6.6%
Top 5 markets shown

Patents

Estimated portfolio value
$83M

56 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where AbCellera Biologics was the backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across AbCellera Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where AbCellera Biologics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        AbCellera Biologics's portfolio, mapped.

        Stage
        Period
        5 of 5 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about AbCellera Biologics on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See AbCellera Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles